Abbott Laboratories reported its third-quarter 2024 earnings, surpassing market expectations. The company posted adjusted earnings per share (EPS) of $1.21, exceeding the forecasted $1.20. Revenue for the quarter reached $10.64 billion, beating the estimated $10.55 billion. Key drivers of this performance included strong sales of glucose-monitoring products and other medical devices. Abbott also reported a year-over-year revenue increase of 4.9% and an organic sales growth of 8.2%, excluding COVID-19 testing. The company has raised its full-year EPS guidance midpoint and now expects adjusted EPS for the fourth quarter to range between $1.31 and $1.37. Additionally, Abbott announced a share buyback program of up to $7 billion. The GAAP diluted EPS was reported at $0.94. Abbott's market cap stands at $201.92 billion.